Claire’s Place Foundation Partners with Woojer to Launch SICK BEATS
June 21, 2021 12:39 ET
|
Claire's Place Foundation
Los Angeles, CA, June 21, 2021 (GLOBE NEWSWIRE) -- Claire’s Place Foundation, a non-profit organization providing support to children and families affected by cystic fibrosis (CF), is pleased to...
Translate Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 06, 2021 16:13 ET
|
Translate Bio, Inc.
-- Advanced infectious disease vaccine programs with Sanofi Pasteur through initiation of COVID-19 clinical trial and publication of preclinical results; Influenza trial anticipated to begin mid-year...
Translate Bio Announces Key Leadership Additions and Promotions
April 19, 2021 07:30 ET
|
Translate Bio, Inc.
-- Seasoned healthcare executive, Brendan Smith, appointed as Chief Financial Officer, bringingstrategic operations and financial leadership -- -- Appointments enhance capabilities across pulmonary...
Translate Bio Appoints Dr. Rand Sutherland as President
March 22, 2021 07:30 ET
|
Translate Bio, Inc.
-- 20 years of combined industry, medical and academic expertise in pulmonary and rare disease to support continued advancement of mRNA therapeutic pipeline -- LEXINGTON, Mass., March 22, 2021 ...
Translate Bio Announces Results from Second Interim Data Analysis from Ongoing Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis (CF)
March 17, 2021 16:05 ET
|
Translate Bio, Inc.
-- First inhaled mRNA therapeutic delivered in multiple doses to the lungs of CF patients is generally safe and well tolerated; no observed pattern of increases in ppFEV1 -- -- Data supports...
Translate Bio Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Progress
February 25, 2021 16:05 ET
|
Translate Bio, Inc.
-- Additional interim data expected in early Q2 from Phase 1/2 clinical trial of MRT5005 for the treatment of cystic fibrosis (CF) -- -- Two infectious disease mRNA vaccine programs expected to enter...
Translate Bio Announces Timing of Interim Results from mRNA Therapeutic Clinical Trial in Patients with Cystic Fibrosis; Data Expected in Early Q2 2021
January 07, 2021 07:30 ET
|
Translate Bio, Inc.
-- MRT5005 is the first clinical-stage mRNA therapeutic with nebulized delivery to the lung and first to be administered in multiple doses for the treatment of a chronic genetic disease -- --...
Translate Bio to Participate in Upcoming Investor Conferences
November 12, 2020 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Highlights mRNA Platform Potential for the Treatment of Cystic Fibrosis (CF) at the 34th Annual North American Cystic Fibrosis Conference
October 07, 2020 16:05 ET
|
Translate Bio, Inc.
-- Lead candidate MRT5005 leverages Translate Bio’s proprietary LNP and mRNA platform and is the only clinical-stage mRNA therapeutic in development for the treatment of CF -- -- Second CF program,...
Translate Bio to Participate in Upcoming Investor Conferences
September 29, 2020 16:05 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...